Skip to content

Prof. Anthony Chan

252
Prof. Anthony Chan
陳德章教授
Share
qualifications
MBBS (Lond), MD (CUHK), FRCP (Lond, Edin, Glas), FHKCP, FHKAM (Medicine)
rank
Li Shu Fan Medical Foundation Professor of Clinical Oncology
Director, The Chinese University of Hong Kong Clinical Trial Centre
Director, The Hong Kong Cancer Institute
Associate Director, State Key Laboratory of Translational Oncology
Director, Sir YK Pao Centre for Cancer, Prince of Wales Hospital
Cluster Coordinator (Clinical Oncology), New Territories East Cluster

Pro-Vice-Chancellor / Vice-President
Master, Wu Yee Sun College
orcid
0000-0002-6912-8091
email
anthonytcchan@cuhk.edu.hk

Specific Research / Sites of Interest


  • Clinical and translational research in Nasopharyngeal Carcinoma (NPC)

Short Biography

Professor Anthony Chan is Pro-Vice-Chancellor / Vice-President, Li Shu Fan Medical Foundation Professor of Clinical Oncology, Director of The Chinese University of Hong Kong Clinical Trial Centre, Director of the Hong Kong Cancer Institute, Director of the Sir YK Pao Centre for Cancer, Associate Director of State Key Laboratory of Translational Oncology, and Master of Wu Yee Sun College at The Chinese University of Hong Kong.

Professor Chan conducted pivotal studies setting new treatment standards in multimodality approaches in nasopharynx cancer, developed the clinical applications of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in this disease. He has published extensively in international journals, and also delivered hundreds of international lectures. He has published reviews in Lancet and Nature Reviews Clinical Oncology as well as European Society for Medical Oncology (ESMO) treatment guidelines for Nasopharyngeal Cancer. He has served on the Editorial Board of Journal of Clinical Oncology and has been Associate Editor of Annals of Oncology since 2014. Professor Chan was honoured with the 2023 ESMO Lifetime Achievement Award in recognition for his leadership and outstanding research in nasopharyngeal cancer.

Most Representative Publications

1. Chan A.T.C., Hui E.P., Ma B.B.Y. (2025). The arrival of antibody drug conjugates in nasopharyngeal cancer. The Lancet (2025).
2. Lam W.K.J., Ma, B.B.Y., King A.K., Malki Y., Chan K.C.A., Chan A.T.C. (2025). Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines. Nature Reviews Clinical Oncology (2025).
3. Lam W.K.J., Kang G.N., Chan C.M.L., Lee V.C.T., Ma M-J.L., Zhou Q., Jiang P.Y., Tse I.O.L., King A.D., Wong K.C.W., Hui E.P., Ma B.B.Y., Chan A.T.C., Chan K.C.A., Lo Y.M.D. (2025). Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma. Cancer Cell, 43(4), 728-739.
4. Chan A.T.C., Lee V.H.F., Hong R.-L., Ahn M.-J., Chong W.Q., Kim S.-B., Ho G.F., Caguioa P.B., Ngamphaiboon N., Ho C., Aziz M.A.S.A., Ng Q.S., Yen C.-J., Soparattanapaisarn N., Ngan R.K.-C., Kho S.K., Tiambeng M.L.A., Yun T., Sriuranpong V., Algazi A.P., Cheng A., Massarelli E., Swaby R.F., Saraf S., Yuan J., Siu L.L. (2023). Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Annals of Oncology, 34(3), 251-261.
5. Chan D.C.T., Lam W.K.J., Hui E.P., Ma B.B.Y., Chan C.M.L., Lee V.C.T., Cheng S.H., Gai W., Jiang P., Wong K.C.W., Mo F., Zee B., King A.D., Le Q.T., Chan A.T.C., Chan K.C.A., Lo Y.M.D. (2022). Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma. Annals of Oncology, 33(8), 794-803.
6. Ma B.B., Hui E.P., Chan A.T.C. (2021). The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nature Medicine, 27(9), 1512-1513.
7. Wong K.C.W., Hui E.P., Lo K.W., Lam W.K.J., Johnson D., Li L., Tao Q., Chan K.C.A., To K.F., King A., Ma B.B., Chan A.T.C. (2021). Nasopharyngeal carcinoma: an evolving paradigm. Nature Reviews Clinical Oncology, 18(11), 679-695.
8. Bossi P., Chan A.T., Licitra L., Trama A., Orlandi E., Hui E.P., Halamkova J., Mattheis S., Baujat B., Hardillo J., Smeele L., van Herpen C., Castro A., Machiels J.P. (2021). Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(4), 452-465.
9. Chen Y.P., Ismaila N., Chua M.L.K., Colevas A. D., Haddad R., Huang S.H., Wee J.T.S., Whitley A.C., Yi J.L., Yom S.S., Chan A.T.C., Hu C.S., Lang J.Y., Le Q.T., Lee A.W.M., Lee N., Lin J.C., Ma B., Morgan T.J., Shah J., Sun Y., Ma J. (2021). Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. Journal of Clinical Oncology, 39(7), 840-859.
10. Hui E.P., Li W.F., Ma B.B., Lam W.K.J., Chan K.C.A., Mo F., Ai Q.Y.H., King A.D., Wong C.H., Guo R., Poon D.M.C., Tong M., Li L., Lau T.K.H., Wong K.C.W., Lam D.C.M., Lo Y.M.D., Ma J., Chan A.T.C. (2020). Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Annals of Oncology, 31(6), 769-779.
11. Chen Y.P., Chan A.T.C., Le Q.T., Blanchard P., Sun Y., Ma J. (2019). Nasopharyngeal carcinoma. The Lancet, 394(10192), 64-80.
12. Lam W.K.J., Jiang P., Chan K.C.A., Peng W., Shang H., Heung M.M.S., Cheng S.H., Zhang H., Tse O.Y.O., Raghupathy R., Ma B.B.Y., Hui E.P., Chan A.T.C., Woo J.K.S., Chiu R.W.K., Lo Y.M.D. (2019). Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nature Communications, 10(1), Article 3256.
13. Chan A.T.C., Hui E.P., Ngan R.K.C., Tung S.Y., Cheng A.C.K., Ng W.T., Lee V.H.F., Ma B.B.Y., Cheng H.C., WONG F.C.S., Loong H.H.F., Tong M., Poon D.M.C., Ahuja A.T., King A.D., Wang K., Mo F., Zee B.C.Y., Chan K.C.A., Lo Y.M.D. (2018). Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: A randomized controlled trial. Journal of Clinical Oncology, 36(31), 3091-3100.
14. Ma B.B.Y., Lim W.T., Goh B.C., Hui E.P., Lo K.W., Pettinger A., Foster N.R., Riess J.W., Agulnik M., Chang A.Y.C., Chopra A., Kish J.A., Chung C.H., Adkins D.R., Cullen K.J., Gitlitz B.J., Lim D.W., To K.F., Chan K.C.A., Lo Y.M.D., King A.D., Erlichman C., Yin J., Costello B.A., Chan A.T.C. (2018). Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of Clinical Oncology, 36(14), 1412-1418.
15. Chan K.C.A., Woo J.K.S., King A., Zee B.C.Y., Lam W.K.J., Chan S.L., Chu S.W.I., Mak C., Tse I.O.L., Leung S.Y.M., Chan G, Hui E.P., Ma B.B.Y., Chiu R.W.K., Leung S.F., van Hasselt A.C., Chan A.T.C., Lo Y.M.D. (2017). Analysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancer. The New England Journal of Medicine, 377(6), 513-522.
16. Li Y.Y., Chung G.T., Lui V.W., To K.F., Ma B.B., Chow C., Woo J.K., Yip K.Y., Seo J., Hui E.P., Mak M.K., Rusan M., Chau N.G., Or Y.Y., Law M.H., Law P.P., Liu Z.W., Ngan H.L., Hau P.M., Verhoeft K.R., Poon P.H., Yoo S.K., Shin J.Y., Lee S.D., Lun S.W., Jia L., Chan A.W., Chan J.Y., Lai P.B., Fung C.Y., Hung S.T., Wang L., Chang A.M., Chiosea S.I., Hedberg M.L., Tsao S.W., van Hasselt A.C., Chan A.T., Grandis J.R., Hammerman P.S., Lo K.W. (2017). Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Communications, 8, Article 14121.
17. Chua M.L., Wee J.T., Hui E.P., Chan A.T. (2016). Nasopharyngeal carcinoma. The Lancet, 387(10022), 1012-1024.
18. Blanchard P., Lee A., Marguet S., Leclercq J., Ng W.T., Ma J., Chan A.T., Huang P.Y., Benhamou E., Zhu G., Chua D.T., Chen Y., Mai H.Q., Kwong D.L., Cheah S.L., Moon J., Tung Y., Chi K.H., Fountzilas G., Zhang L., Hui E.P., Lu T.X., Bourhis J., Pignon J.P. (2015). Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. The Lancet Oncology, 16(6), 645-655.
19. Mesia R., Henke M., Fortin A., Minn H., Yunes Ancona A.C., Cmelak A., Markowitz A.B., Hotte S.J., Singh S., Chan A.T., Merlano M.C., Skladodwski K., Zhang A., Oliner K.S., VanderWalde A., Giralt J. (2015). Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomized, controlled, open-label phase 2 trial. The Lancet Oncology, 16(2), 208-220.
20. Lee A.W., Ma B.B., Ng W.T., Chan A.T. (2015). Management of nasopharyngeal carcinoma: Current practice and future perspective. Journal of Clinical Oncology, 33(29), 3356-3364.
21. Leung S.F., Chan K.C., Ma B.B., Hui E.P., Mo F., Chow K.C., Leung L., Chu K.W., Zee B., Lo Y.M., Chan A.T. (2014). Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Annals of Oncology, 25(6), 1204-1208.